198 related articles for article (PubMed ID: 33076776)
21. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.
Sawka AM; Thephamongkhol K; Brouwers M; Thabane L; Browman G; Gerstein HC
J Clin Endocrinol Metab; 2004 Aug; 89(8):3668-76. PubMed ID: 15292285
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer.
Taylor H; Hyer S; Vini L; Pratt B; Cook G; Harmer C
Eur J Endocrinol; 2004 May; 150(5):649-53. PubMed ID: 15132720
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
24. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
25. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
Fatourechi V; Hay ID
Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
[TBL] [Abstract][Full Text] [Related]
26. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
28. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
Van Nostrand D; Aiken M; Atkins F; Moreau S; Garcia C; Acio E; Burman K; Wartofsky L
Thyroid; 2009 Aug; 19(8):849-55. PubMed ID: 19281428
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic whole body scan (pre-therapy scan) in differentiated thyroid cancer: A single center community hospital experience.
Santhanam P; Driscoll HK; Venkatraman P
Indian J Cancer; 2016; 53(1):178-80. PubMed ID: 27146773
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
31. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
32. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.
Lee HJ; Rha SY; Jo YS; Kim SM; Ku BJ; Shong M; Kim YK; Ro HK
Am J Clin Oncol; 2007 Feb; 30(1):63-8. PubMed ID: 17278897
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
35. Radioactive Iodine for Papillary Thyroid Carcinoma.
Chan WWL; Kwong DLW
Methods Mol Biol; 2022; 2534():225-241. PubMed ID: 35670979
[TBL] [Abstract][Full Text] [Related]
36. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
37. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
38. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas.
Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
Thyroid; 2014 Aug; 24(8):1289-96. PubMed ID: 24731156
[TBL] [Abstract][Full Text] [Related]
39. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
